COMMUNIQUÉS West-GlobeNewswire

Easton Pharmaceuticals Announces Signing and Commencement of $2,600,000 Framing Contract to Construct 150 Homes

02/01/2019 - 16:20

TORONTO, ON, Jan. 02, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Easton Pharmaceuticals Inc. (OTC: EAPH ) Announces that it has closed on a Construction Agreement and has started operations on a $2,600,000 CDN framing [...]

Holding(s) in Company

02/01/2019 - 16:15

Holding(s) in Company January 2, 2019 – Shire plc (LSE: SHP, NASDAQ: SHPG) 1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii : Shire Plc JE00B2QKY057 1b. [...]

OraSure Technologies, Inc.: Updated Release to Clarify Timing of Presentation

02/01/2019 - 15:43

OraSure Technologies to Present at the 37th Annual J.P. Morgan Healthcare Conference BETHLEHEM, Pa., Jan. 02, 2019 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic [...]

Cambrex Completes Acquisition of Avista Pharma Solutions

02/01/2019 - 15:40

EAST RUTHERFORD, N.J., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage [...]

Coherus BioSciences Appoints Darlene Horton, M.D., Chief Medical and Regulatory Affairs Officer

02/01/2019 - 15:30

REDWOOD CITY, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced the addition of Darlene Horton, M.D. as Chief Medical and Regulatory Affairs Officer. She assumed her [...]

Coherus BioSciences Management to Present at The 37th Annual J.P. Morgan Healthcare Conference

02/01/2019 - 15:30

REDWOOD CITY, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at the 37 th annual J.P. Morgan healthcare conference on Tuesday, [...]

Outlook Therapeutics Closes Third Tranche of $20 Million Private Placement

02/01/2019 - 15:15

CRANBURY, N.J., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”) today announced that it closed on the third tranche (of four) of its $20.0 million private placement of common [...]

Cerner to Present at 37th Annual J.P. Morgan Healthcare Conference

02/01/2019 - 15:00

KANSAS CITY, Mo, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Cerner Corporation (Nasdaq: CERN) announced today that Chairman and CEO Brent Shafer and Executive Vice President and Chief Financial Officer Marc Naughton will present [...]

Obalon to Host Call to Provide Update on Commercial Strategy Post FDA Approval of the Obalon Navigation System

02/01/2019 - 15:00

SAN DIEGO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric [...]

Innovation Pharmaceuticals Receives New Brilacidin Patent, Further Expanding Intellectual Property Estate

02/01/2019 - 15:00

BEVERLY, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage pharmaceutical company, reported today that the U.S. Patent & Trademark Office recently [...]

Oxford Immunotec to Present at the 37th Annual J.P. Morgan Healthcare Conference

02/01/2019 - 15:00

OXFORD, United Kingdom and MARLBOROUGH, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that Dr. Peter Wrighton-Smith, Chief [...]

Obalon Announces Promotion of Kelly Huang, Ph.D. To Chief Executive Officer

02/01/2019 - 14:45

SAN DIEGO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ: OBLN ), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric [...]

Acer Therapeutics Announces In-license of Osanetant from Sanofi

02/01/2019 - 14:30

Acer acquires worldwide rights to clinical-stage NK3 receptor antagonist NEWTON, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER), a pharmaceutical company focused on the acquisition, [...]

Align Technology to Announce Fourth Quarter and 2018 Results on January 29, 2019

02/01/2019 - 14:30

SAN JOSE, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Align Technology, Inc. (Nasdaq: ALGN) announced today that the Company will report fourth quarter and 2018 financial results on Tuesday, January 29, 2019 after the [...]

Hemispherx Biopharma Inc. Announces Advancement in Expanded Access Program for Ampligen in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

02/01/2019 - 14:30

Second Large Shipment Dispatched to Second Major Clinic OCALA, Fla., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma R&D and emerging commercial growth company [...]

AIT Strengthens Executive Leadership Team with Appointment of Chief Commercial Officer

02/01/2019 - 14:30

Former Worldwide Vice President at Becton Dickinson (BD), Duncan Fatkin, Appointed AIT’s Chief Commercial Officer GARDEN CITY, N.Y. and REHOVOT, Israel, Jan. 02, 2019 (GLOBE NEWSWIRE) -- AIT Therapeutics, Inc. (OTCQB: [...]

Progenics Pharmaceuticals Expands Leadership Team with Appointment of Asha Das, M.D. as Chief Medical Officer

02/01/2019 - 14:30

NEW YORK, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, today [...]

Teligent, Inc. Announces FDA Approval of Gentamicin Sulfate Ointment USP, 0.1%

02/01/2019 - 14:30

BUENA, N.J., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT), a New Jersey-based specialty generic pharmaceutical company, today announced it has received approval of the Company’s abbreviated new drug [...]

Sarepta Therapeutics Enters into Long-term Strategic Relationship with Aldevron for GMP-grade Plasmid in Support of Gene Therapy Development and Commercial Manufacturing Strategy

02/01/2019 - 14:30

-- Agreement provides Sarepta with committed capacity and dedicated manufacturing slots for GMP-grade plasmid production for its micro-dystrophin Duchenne muscular dystrophy (DMD) gene therapy program, as well as [...]